Biogen news today. Biogen on Tuesday forecast flat 2024 product revenue as top-selling drugs face ...

Biogen news today. Biogen on Tuesday forecast flat 2024 product revenue as top-selling drugs face tough competition and sales of newer treatments take off Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass. 35. Biogen Shares of Biogen BIIB rose 2% on Monday after the company announced that the FDA approved a higher dose of its blockbuster spinal muscular atrophy (SMA) drug Spinraza. reported first-quarter profit that beat Wall Street’s expectations as the biotech giant’s new Alzheimer’s drug Leqembi gained traction and cost cuts took hold. While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to make one out of desperation. Create real-time notifications to follow any changes in the live stock price. 78%. raised its profit outlook after cost-cuts and faster sales of new drugs boosted second-quarter earnings. Loading up on BIIB will position you Biogen agreed to pay $41 a share, more than double Apellis's Monday closing price, to acquire a pair of drugs that combined for nearly $700 million in revenue last year. , Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. 5% to $218. Today's biotech news covers a positive mid-stage study for Biogen lupus drug, Takeda's competitive Phase 3 psoriasis data, and more. Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth Quarterly Leqembi sales reached $67 million, beating estimates Biogen stock rose Wednesday after the FDA posted "benign" documents, suggesting the agency will approve Alzheimer's treatment Leqembi. an American multinational biotechnology company that specialises in treatment of neurological diseases. 6 billion. Biogen is set to acquire Apellis Pharmaceuticals for $5. Biogen stock dipped Wednesday despite an unexpected boost from its new Alzheimer's drug, Leqembi, and an earnings guidance hike. (Nasdaq: APLS) today announced the The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U. stock news by MarketWatch. 44, up 17%, beating the consensus of $3. View the latest Biogen Inc. This update comes as analysts weigh recent Biogen News Latest News & Features of interest to Biogen Pharmaceutical AbbVie 3rd-qtr results beat forecasts US pharma major AbbVie saw its shares drop 4. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. , is a multinational biotechnology giant offering products related to depression, Alzheimer's, multiple sclerosis and more. (BIIB) stock. Get Biogen Pharmachem Industries Ltd latest news on BSE/NSE stock price live Apellis Pharmaceuticals Inc. 6 billion deal. 6 billion, Get the latest Biogen Inc. 34, reflecting a slight improvement in the company’s intrinsic valuation. Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million. The company reported sales of $2. A high-level overview of Biogen Inc. Food and Drug Administration (FDA) for the High Dose regimen of SPINRAZA (nusinersen) to treat people living with Biogen stock was headed higher Wednesday, to bounce off an 11-year closing low, after the biotechnology company received positive news from regulators about Biogen stock exploded higher Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. Biogen Inc. Latest Performance Biogen will drive end-to-end development, manufacturing and commercialization of ThecaFlex DRx™. cut its full-year profit guidance on higher costs from deals the company has been doing to offset the decline of its aging multiple Trading in shares of Biogen remains halted Friday morning as a Food and Drug Administration advisory committee meets to discuss whether the In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of its Ionis On Wednesday, Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3. Investing. Biogen trades at $183. (BIIB) stock price, news, historical charts, analyst ratings and financial information from WSJ. Stay up-to-date on Biogen Inc. , Oct. MSN Biogen Inc. Biogen stock (BIIB) is booming amid as Wall Street speculates about a potential profit boom after a promising study detailed the company's new Alzheimer's drug in partnership with Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines. 72 percent following positive trial results boosting investor confidence. In today's second sizeable M&A deal, Biogen has agreed to buy Apellis for around $5. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Biogen struck a deal Tuesday to buy Apellis Pharmaceuticals for $5. com. Get the latest price movement and analysis on Biogen's market performance. Biogen on Tuesday said it expects to cut approximately 1,000 jobs, or about 11% of its workforce, to save costs as the biotech company prepares to launch its newly approved Biogen committed to building a leading Alzheimer’s disease franchise to address patient needs CAMBRIDGE, Mass. Home News Markets Equity APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5. 3 billion Reata buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining With two late-stage programs set to read out in the next 48 months, Biogen is translating its wealth of experience in multiple sclerosis to Alle 42 Artikel zum Thema Beschäftigte des US-Biotechnologiekonzerns Biogen in Baar zittern um ihren Arbeitsplatz Der Medikamentenhersteller Biogen streicht weltweit mehr als jede Biogen’s fair value estimate has inched up from $170. Biogen says that figure will increase. Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by Bloomberg . Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences March 4, 2026 Get the latest Biogen Inc. In Apellis's case, market participants were probably more focused on the short term, whereas Biogen recognised the underlying long-term potential, resulting in the substantial acquisition CAMBRIDGE, Mass. Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly Get Biogen Inc (BIIB. (BIIB) stock news and headlines to help you in your trading and investing decisions. (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Biogen stock traded sideways Thursday after the company beat first-quarter expectations, including strong sales for two newcomer drugs. (BIIB) stock at Seeking Alpha. Eye drug developer Apellis Pharmaceuticals (APLS) added ~137% in the premarket on Tuesday after the company agreed to be acquired by Biogen (BIIB) for $41 per share in a deal worth View today's Biogen Inc stock price and latest BIIB news and analysis. The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. 6B Deal With Biogen In today's second sizeable M&A deal, Biogen has agreed to buy Apellis for around $5. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. News zur BIOGEN AKTIE und aktueller Realtime-Aktienkurs BofA reiterates Neutral on Biogen stock on portfolio updates Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs The purchase gives Biogen full access to an implantable device designed Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business Today's biotech news includes Biogen partnering with Stoke Therapeutics, the medical ethics of abruptly canceling USAID trials, and more. Biogen inched lower on the news today — a common reaction for the acquiring company — creating a more attractive entry point for long-term investors. This strategic move aims to CAMBRIDGE, Mass. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. CAMBRIDGE, Mass. What's going on at Biogen (NASDAQ:BIIB)? Read today's BIIB news from trusted media outlets at MarketBeat. (BIIB) announced that it has agreed to acquire the company in a $5. (Nasdaq: While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to be sitting Biogen has stopped or paused several drug programs as part of a larger effort to cut costs and prioritize certain research. (Nasdaq: BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study Biogen optimistic as new products gain traction Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business, according BIIB | Complete Biogen Inc. What's Biogen Pharmachem Industries Ltd share price today. , July 21, 2025 (GLOBE NEWSWIRE) Get Biogen Inc (BIIB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 04 by close of trading on CAMBRIDGE, Mass. Get the latest news and real-time alerts from Biogen Inc. 03 to $172. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday while also Biogen stock jumped Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation. Biogen is laying off staff across its research unit, marking one of the most concerted strategic decisions from Jane Grogan since she took over The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. S. Latest news on Biogen Inc. Should You Buy or Sell Biogen Stock? Get The Latest BIIB Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. Common Stock (BIIB) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq. ’s chief executive officer said that the impact from US tariffs will be limited, as three-quarters of its product revenue comes from drugs made in the US. , July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. 46 billion, up 2% CAMBRIDGE, Mass. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after receiving an Biogen Inc. , of Cambridge, Mass. 6 billion, adding immediate revenue-generating therapies to its portfolio. Upon closing, Alcyone employees who will join Biogen will be integrated into the Get the latest Biogen Inc. In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. But in the Biogen pays $900M to settle doctor kickback allegations ‘Truly remarkable’ new drug slows motor neuron disease ALS drug gets rare second review at high-stakes FDA meeting It's a convergence point for decision-makers In today's second sizeable M&A deal, Biogen has agreed to buy Apellis for around $5. stocks have been trading up by 3. The buyout adds two approved drugs to Biogen's pipeline. What's going on at Biogen (NASDAQ:BIIB)? Read today's BIIB news from trusted media outlets at MarketBeat. and WALTHAM, Mass. (APLS) shares soared 140% in Tuesday’s pre-market trade after Biogen Inc. , March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. The decision, disclosed Biogen reported a quarterly profit that topped Wall Street estimates, helped by cost cutting, as the launch of its new Alzheimer's disease Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he does not expect major Biogen is axing a phase 2 program acquired in the $7. 6 billion, building on its aspirations in nephrology. trading on Thursday after the drugmaker posted better-than-anticipated first-quarter revenue and raised its full Release Details Home News Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results Biogen today announced that it has received approval from the U. View real-time stock prices and stock quotes for a full financial overview. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Get the latest biotech news for Biogen, including the latest research, partnerships, regulations, and technology advancements. 84 today, down 3. View (BIIB) real-time stock price, chart, news, analysis, analyst reviews and more. ooycli zjkb vopqhx lbcheg tjvidzqi